Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) finished Friday with an addition of $0.44 to close at $40.56, an upside of 1.10 percent. An average of 776,360 shares of common stock have been traded in the last five days. There was a gain of $2.35 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 917,345 shares traded, while the 50-day average volume stands at 912,312.
ARWR stock has increased by 25.96% in the last month. The company shares reached their 1-month lowest point of $30.01 on 12/19/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $26.81 and a high of $70.09 in 52 weeks. It has reached a new high 1 time so far this year and lost -38.82% or -$25.74 in price. In spite of this, the price is down -42.13% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ARWR stock investors should be aware that Arrowhead Pharmaceuticals Inc. (ARWR) stock had its last reported insider trading activity 2 days ago on Dec 29. In this transaction, the insider spent $1,225,000. Chief Medical Officer, San Martin Javier, disposed of 19,500 shares at a price of $29.99 on Nov 21. The insider now owns more than $584,738 worth of shares. Prior to that, Chief Executive Officer Anzalone Christopher Richard went on to Sale 146,388 shares at $51.91 each on Feb 11. An amount of $7,598,864 was transacted.
Arrowhead Pharmaceuticals Inc. (ARWR) stock’s beta is 1.27. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17.64, the price-to-book (PB) ratio at 10.79.
The quick ratio of Arrowhead Pharmaceuticals Inc. for the three months ended June 29 was 2.90, and the current ratio was 2.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $421.74 million compared to revenue of $243.23 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Arrowhead Pharmaceuticals Inc.’s return on assets was -25.30%.
For the three-month period that ended June 29, Arrowhead Pharmaceuticals Inc. had $268.39 million in cash. The company posted a net income of -$85.51 million in the quarter, while revenues were grew 25.89%. The analyst consensus anticipated Arrowhead Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.51 per share, but it turned out to be -$0.68, a -33.30% surprise.
From a technical analysis perspective, let’s take a brief look at Arrowhead Pharmaceuticals Inc. (ARWR) price momentum. RSI 9-day as of the close on 30 December was 76.36%, suggesting the stock is Overbought, with historical volatility in this time frame at 65.34%.
As of today, ARWR’s price is $38.93 +6.15% or $2.35 from its 5-day moving average. ARWR is currently trading +26.67% higher than its 20-day SMA and -10.76% lower than its 100-day SMA. However, the stock’s current price level is +25.26% above the SMA50 and -7.23% below the SMA200.
The stochastic %K and %D were 93.54% and 91.19%, respectively, and the average true range (ATR) was 1.88. With the 14-day stochastic at 99.43% and the average true range at 1.89, the RSI (14) stands at 69.75%. The stock has reached 2.30 on the 9-day MACD Oscillator while the 14-day reading was at 4.07.
Morgan Stanley launched coverage on Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) in its analyst report released on September 09, 2022. The firm assigned the stock an Equal-weight rating. The consensus rating for Arrowhead Pharmaceuticals Inc. (ARWR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ARWR, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is ARWR’s price target for the next 12 months?
Analysts predict a range of price targets between $31.00 and $92.00, with a median target of $75.00. Taking a look at these predictions, the average price target given by analysts for Arrowhead Pharmaceuticals Inc. (ARWR) stock is $69.69.